Clinical significance of CD133 and Nestin in astrocytic tumor: The correlation with pathological grade and survival

Abstract

Background We aimed to investigate the interaction between CD133 and Nestin and further assessed the correlation of CD133 and Nestin with clinicopathological characteristics and survival in patients with astrocytic tumor. Methods Totally 127 patients with astrocytic tumor underwent surgical resection were enrolled. Patients’ age, gender, and World Health Organization (WHO) grade were recorded, and the survival data were extracted from the follow‐up records. The expressions of CD133 and Nestin in astrocytic tumor tissues were analyzed by immunohistochemistry assay. The WHO grade I and II astrocytic tumors were defined as low‐grade astrocytic tumors (LGA), the WHO grade III and IV astrocytic tumors were defined as high‐grade astrocytic tumors (HGA). Results There were 79 (62.2%), 34 (26.8%), 14 (11.0%), and 0 (0.0%) patients with CD133 negative, low, moderate, and high expression, respectively; 7 (5.5%), 47 (37.0%), 20 (15.7%), 53 (41.7%) patients with Nestin negative, low, moderate, high expression, respectively. CD133 and Nestin were both correlated with advanced WHO grade but not with age or gender, and positive correlation was observed between CD133 and Nestin. For survival, both CD133 and Nestin were correlated with unfavorable overall survival (OS), and further analysis illustrated that Nestin but not CD133 independently predicted poor OS. Subgroup analysis also revealed that Nestin but not CD133 negatively associated with shorter OS in LGA patients, while both CD133 and Nestin were correlated with poor OS in HGA patients. Conclusion CD133 and Nestin present as potential biomarkers for advanced pathological grade and poor survival in patients with astrocytic tumor.

Survival nomogram for patients with bone metastatic renal cell carcinoma: A population-based study

“…Tumor-related pathological characteristics have also been found to be correlated with the prognosis of cancer patients, such as pathological grade, T-stage, N-stage and multi-organ metastasis (21). Cancer stem cells were one of the focuses of current studies (22). The pathological grade of the tumor was positively correlated with the stemness of the cancer cells (22).…”

“…Cancer stem cells were one of the focuses of current studies (22). The pathological grade of the tumor was positively correlated with the stemness of the cancer cells (22). High-grade tumors were often accompanied by a high degree of malignancy and strong invasiveness, which has an adverse impact on the prognosis of patients (23).…”

The relationship among integrin alpha 7, CD133 and Nestin as well as their correlation with clinicopathological features and prognosis in astrocytoma patients

“…CD133 and Nestin are two heavily investigated CSC markers, meanwhile they are commonly co-expressed in neural stem cells [29]. In the clinical eld, CD133 and Nestin correlated with advanced WHO grade, also their high expressions correlate with shorter OS in astrocytoma patients [15]. However, no relevant research reports their relationship with ITGA7 in astrocytoma patients.…”

“…In addition, in the clinical eld, ITGA7 high expression correlates with poor prognosis in clear renal cell carcinoma patients, rectal cancer patients and breast cancer patients [10,13,14]. Furthermore, ITGA7 not only acts as a potential cancer stem cell (CSC) marker, but also regulates multiple other CSC marker expressions (including CD44, CD90, CD133, SOX2, OCT3/4 and NANOG), meanwhile, these CSC markers (such as CD133 and Nestin) correlate with shorter overall survival (OS) in astrocytoma patients [9,11,[15][16][17]. Given the fact that ITGA7 regulates CSC marker expressions in several cancers, besides CD133 and Nestin are well-characterised CSC markers in astrocytoma, we hypothesized that ITGA7 assessment might have a potentially clinical value in astrocytoma patients [18][19][20][21].…”

The Relationship Among Integrin Alpha 7, CD133 and Nestin as Well as Their Correlation With Clinicopathological Features and Prognosis in Astrocytoma Patients

“…In addition, in the clinical eld, ITGA7 high expression correlates with poor prognosis in clear renal cell carcinoma patients, rectal cancer patients and breast cancer patients [10,13,14]. Furthermore, ITGA7 not only acts as a potential cancer stem cell (CSC) marker, but also regulates multiple other CSC marker expressions (including CD44, CD90, CD133, SOX2, OCT3/4 and NANOG), meanwhile, these CSC markers (such as CD133 and Nestin) correlate with shorter overall survival (OS) in astrocytoma patients [9,11,[15][16][17]. Given the fact that ITGA7 regulates CSC marker expressions in several cancers, besides CD133 and Nestin are well-characterised CSC markers in astrocytoma, we hypothesized that ITGA7 assessment might have a potentially clinical value in astrocytoma patients [18][19][20][21].…”